Optimal methods for susceptibility testing of Candida spp. with flucytosine have not been determined. Breakpoints were recommended in 1984, but never validated. In this study, we compared the 1984 recommended macrodilution broth method (using an 80% endpoint) with a modification of the more recent NCCLS-recommended microdilution broth method with three endpointsspectrophotometric 50% and 80% and a no growth endpoint determined by eye. NCCLS and British Society for Medical Mycology (BSMM) breakpoints were also compared. One hundred and fifty isolates comprised of Candida albicans, Candida tropicalis, Candida krusei, Candida glabrata, Candida parapsilosis and Candida lusitaniae were tested. Reproducibility was excellent. For C. albicans (n = 65), the correlation between tests was excellent (>75%), with few major discrepancies (<5%). For C. tropicalis (n = 27), correlation was good (59%), but there were a small number of major discrepancies (up to 11%, depending on breakpoint used). Results by the broth macrodilution method were generally higher than both microdilution methods for C. glabrata (n = 16; correlation of 18.8%), but only one major discrepancy was seen. Ten of the 11 C. parapsilosis isolates tested were susceptible by all methods, regardless of breakpoint chosen, with a correlation of 18.2%, but no major discrepancies were seen. A correlation between all methods (50%) was seen with C. lusitaniae (n = 10), with many isolates resistant or intermediate. In contrast, correlation between methods for C. krusei was poor (<5%); NCCLS microtitre modification produced results that were classified as intermediate or resistant, regardless of the breakpoint used. The methodology for susceptibility testing C. albicans is robust. Additional work to optimize susceptibility testing with flucytosine is necessary for nonalbicans Candida species, especially C. krusei.
Introduction
Serious infections caused by yeasts are an increasing problem due to the immunosuppressive nature of surgery, human immunodeficiency virus (HIV) infection, organ transplantation and the treatment of malignancy. 1 Used as monotherapy, flucytosine (5FC) is often effective, but the development of resistance during therapy is well recognized. 2, 3 For this reason, it is usually used in combination with amphotericin B or occasionally with either fluconazole or itraconazole. A reliable susceptibility testing method is required. At present, there are two recognized methods for in vitro testing of flucytosine: the broth macrodilution method using Yeast Nitrogen Base with 1% glucose (YNBG), as detailed previously by the British Society for Mycopathology 4 [now the British Society for Medical Mycology (BSMM)] and the NCCLS M27-A method. 5 Several modifications of the original NCCLS M27-A broth macrodilution testing method have been adopted in various laboratories. 6 These include the addition of glucose to RPMI-1640 medium to enhance yeast growth and the use of flat-bottomed microtitre plates. The Working Group Report 4 suggested that most yeast isolates, including the standard susceptible strain, have MICs ≤ 1 mg/L and strains with MICs ≥ 16 mg/L may be considered resistant. Breakpoints have also been proposed for the NCCLS M27-A method. 5, 6 However, these are based only on historical and pharmacokinetic data Tel: +44-161-291-5811; Fax: +44-161-291-5806; E-mail: ddenning@man.ac.uk rather than any in vitro-in vivo correlation work. Animal studies have previously shown a relationship between susceptibility testing, using a microtitre method, and in vivo outcome in murine haematogenous candidiasis. 7 In this study, we compared three methods: the broth macrodilution method 4 and two microtitre modifications of the NCCLS M27-A method 5 using either RPMI supplemented with 1.8% glucose (RPMI-G) or YNBG as the test medium, to attempt to correlate results between methods. MICs were also compared according to different endpoint definitions; either no growth or optical density reduction by 50% or 80% compared with the drug-free control. Few inter-species comparisons have been carried out; therefore, we have compared results for six pathogenic Candida species.
Materials and methods

Yeast strains
The three methods were compared using 150 isolates of Candida belonging to six different species. 
Flucytosine
Flucytosine was provided by Roche Products Limited, Hertfordshire, UK. The powder was dissolved in sterile distilled water to produce a stock solution of 1280 mg/L. This was then dispensed into aliquots and stored at -20°C in the dark until required.
Media
For the macrodilution susceptibility testing method and one of the microtitre methods, YNBG (Difco, Surrey, UK) was used. RPMI-1640 (Sigma, Dorset, UK) supplemented with 1.8% glucose, buffered with MOPS (Sigma) and adjusted to pH 7.0 (RPMI-G) was used for the other microtitre method.
Susceptibility testing
All three methods were carried out simultaneously.
Macrodilution method. The broth macrodilution method employed was that of the 'Report of a Working Group of the British Society for Mycopathology' 4 using 1 mL volumes of YNBG broth in 5 mL glass, loose-capped tubes. The final drug range was 0.03-32 mg/L. Yeast suspensions were prepared by suspending single colonies in sterile distilled water. The final inoculum in the assay was ∼5 × 10 4 cfu/mL. A flucytosine-susceptible strain Candida kefyr San Antonio (SA) was included with each batch of test organisms as a control. In addition, a negative control was included to ensure the sterility of the medium and one tube for each isolate was left drug-free to act as a positive control. The tubes were incubated at 37°C for 48 h in air. The MIC was read visually, with the aid of an 80% inhibition standard tube, 5 and was taken as the lowest drug concentration to inhibit 80% of the growth compared with the positive control.
Microtitre methods. The method used was a microtitre modification of the NCCLS M27-A method 5 in flat-bottomed microtitre plates with either YNBG or RPMI-G broth. The final drug range was 0.03-32 mg/L. The yeast suspensions used for the macrodilution method were then adjusted further, using the appropriate medium, to give a final inoculum of 0.5-2.5 × 10 3 cfu/mL. The C. kefyr SA strain was used as a control. Positive and negative controls were also included. The microtitre plates were incubated in a moist chamber at 37°C for 48 h. After incubation, the microtitre plates were shaken for 5 min to obtain a uniform suspension before reading. The growth in each well was measured by determining the optical density at 490 nm by spectrophotometry. Three different endpoints were then recorded; no growth by eye, and the drug concentrations that reduced the OD 490 by either 50% or 80% when compared with the drug-free control.
Reproducibility
Twenty per cent of the isolates (30/150) were randomly selected and re-tested to establish the reproducibility of each method and each endpoint. Table 1 presents the results obtained for the six ATCC isolates tested, together with the expected MIC range by the NCCLS M27-A method. 5 All ATCC isolates gave results within the recommended limits when tested using the modified NCCLS method with RPMI-G and an 80% endpoint. Table 2 shows the in vitro susceptibilities of all 150 Candida isolates with all three methods. However, in presenting the results, we shall use the modified NCCLS microtitre method with RPMI-G and an 80% endpoint as our reference point, since it gives comparable results to that of the NCCLS M27-A method, 5 and the other two methods will be compared to this. Results will be presented by species, because there are substantial inter-species variations ( Table 2 ). The classifica- Comparisons within microtitre methods. When comparing the different endpoints, only two (3.1%) and five (7.7%) isolates showed differences of more than one doubling dilution with RPMI-G and YNBG microtitre methods, respectively.
Results
Comparison between all methods. Correlation between all three methods was good with over 75% of isolates having MICs within two doubling dilutions (Table 3) . A small percentage of major discrepancies were found when employing either NCCLS (4.6%) or BSMM (1.5%) breakpoints, and these showed varied differences (Table 4) . Comparison between all methods. Overall, the correlation between the different tests was good, with almost 60% of isolates having MICs within two doubling dilutions (Table 3) . Again, a small number of major discrepancies were seen when using either NCCLS (11.1%) or BSMM (3.7%) breakpoints, and these showed varied differences (Table 4) .
C. tropicalis (n = 27)
C. krusei (n = 21)
With Comparison between all methods. Correlation between the three methods was very poor, with <5% of isolates having MICs within two doubling dilutions. Over 70% of isolates showed differences of four or five dilutions (Table 3) . RPMI-G results were significantly higher for most isolates compared with the other two methods. Perhaps surprisingly, there were no major discrepancies when NCCLS breakpoints were Table 3 . Discrepancies between MICs obtained using three different MIC methods
Comparisons were made between a broth macrodilution method using YNBG, and two microtitre methods (using either YNBG or RPMI-G). All MICs were obtained using an 80% endpoint.
Species (n)
MICs ± 2 dilutions (%)
MICs more than ± 5 dilutions (%) Comparisons within microtitre methods. The different endpoints showed a difference of more than one doubling dilution for only one isolate (6.2%) with the YNBG microtitre method. The RPMI-G microtitre method showed no differences between endpoints.
Comparison between all methods. Correlation between methods was poor, with only 18.8% of isolates having MICs within two doubling dilutions ( Table 3 ). The poor correlation resulted mainly from the broth macrodilution method since these results were usually higher than those of either of the microtitre methods. However, since most isolates were susceptible with either breakpoint or any methods, only one major discrepancy was found with BSMM breakpoints (Table 4 ). This isolate was susceptible or intermediate by either microtitre method, but resistant by the broth macrobroth dilution method. No major discrepancies were found when using NCCLS breakpoints.
C. parapsilosis (n = 11)
With either NCCLS 5 or BSMM 4 breakpoints all isolates were susceptible.
Comparisons within microtitre methods. Comparison between the different endpoints showed differences of greater than one doubling dilution for six (54.5%) and one (9.1%) isolate with RPMI-G and YNBG microtitre methods, respectively.
Comparison between all methods. The three methods exhibited a poor correlation, with only 18.2% of strains having MICs within two doubling dilutions. The majority of isolates (72.7%) had MICs that differed by three dilutions ( Table 3) . The YNBG microtitre results were notably lower than those of the other methods; however, no major discrepancies were seen with either breakpoint.
C. lusitaniae (n = 10)
With NCCLS breakpoints, 5 six isolates were resistant and the remainder susceptible. With BSMM breakpoints, 4 six isolates Table 4 .
Major discrepancies resulting in a change of susceptibility category Comparisons within microtitre methods. When analysing the different endpoints, two (20%) and four (40%) isolates were different by more than one doubling dilution with RPMI-G and YNBG microtitre methods, respectively.
Large endpoint variations were noted with this species, with some MICs increasing dramatically as the stringency of the endpoint increased.
Comparison between all methods. Correlation between the three methods showed that 50% of isolates had MICs within two doubling dilutions (Table 3) . Three major discrepancies (30%) were seen with both NCCLS and BSMM breakpoints (Table 4 ). These three isolates were resistant by RPMI-G microtitre, susceptible by YNBG microtitre and either susceptible (NCCLS breakpoints) or intermediate (BSMM breakpoints) in the broth macrodilution test.
Reproducibility
Of the 20% of isolates (30/150) re-tested with all seven endpoints (210 results), 15 (7.1%) results in nine isolates differed by more than one dilution and one (0.5%) by more than two dilutions. This was an isolate of C. albicans tested using the YNBG microtitre method, with a 50% endpoint that rose from 4 to >32 mg/L.
Discussion
Historically, most susceptibility testing with flucytosine has been carried out with YNB broth. 9 Since the drug's introduction, early experiments had established that media containing complex nitrogen sources antagonized its activity. 9 In 1984, a Report of a Working Group of the British Society for Mycopathology was published. 4 Its main concern was to recommend appropriate laboratory methods for flucytosine susceptibility testing. The Group found that the in vitro activity of flucytosine is very dependent on the conditions of testing: medium, incubation time, inoculum and reading. These factors were reflected in disagreement between numerical results for individual strains among members of the Group. 4 In 1982, the first subcommittee of the NCCLS on antifungal susceptibility testing was formed. This subcommittee was charged with developing a reference method that might improve inter-laboratory reproducibility. A comparison of macrodilution and microdilution tests with flucytosine with RPMI-1640 showed equivalence or lower MICs with microdilution, especially with C. tropicalis. 10, 11 Other collaborative work indicated better inter-laboratory agreement (65-90%) with flucytosine using a smaller inoculum, a 2 day incubation period and a 1+ turbidity growth endpoint. 12 Agreement with C. lusitaniae was worse than other species and C. krusei was not included. Selection of quality control isolates involved repetitive testing of 10 candidate strains and three Candida isolates were selected with a range of flucytosine MICs. 8, 13, 14 Agreement for C. albicans with the supplementation of the RPMI-1640 with 1.8% glucose was 98.1% in a microtitre format. 15 Alteration of pH barely affected the results. 16 In this study, we identified a number of resistant isolates of C. albicans (10.8%), C. tropicalis (14.8%) and C. lusitaniae (60%). In addition, we found all C. krusei isolates to be intermediate to flucytosine. This figure is three times higher than that previously published. 6 These rates of reduced susceptibility were in contrast to that found by others, 6 where much lower levels of resistance were observed. However, the previous study was carried out in Spain where flucytosine is rarely used; therefore our results may reflect greater use of this drug in the UK. Interestingly though, C. glabrata was always found to be susceptible in our study, compared with over 25% of isolates showing intermediate resistance in the Spanish study. 6 C. parapsilosis was also fully susceptible in the present study, thus agreeing with the findings of others. 6 Most published studies of flucytosine have compared the NCCLS method 5 with commercial tests, such as Etest, 17 Sensititre YeastOne Colorimetric Antifungal Panel 18 and Fungitest, 19 with varying degrees of success. None of these tests utilizes YNB broth as the test medium; however, YNB broth has previously been used to carry out flucytosine susceptibility testing against Candida species. 20,21 Galgiani et al. 21 showed that variations in the formulation of YNB did not affect the susceptibility testing of flucytosine to any significant extent. In addition, YNB broth has previously been used to test flucytosine against Cryptococcus neoformans, 22 where it was found to give the widest range of MICs compared with other media, which included RPMI-1640 with and without additional glucose. It is also noted in the NCCLS document 5 that YNB broth may improve clinical relevance when testing C. neoformans. Nevertheless, no comparisons between the methods of the NCCLS 5 and BSMM 4 with any Candida species have been published to date.
A few studies have shown a correlation with flucytosine susceptibility testing and outcome in vivo. Stiller et al. 23 found a correlation between a broth macrodilution method and in vivo response in C. albicans. Isolates with an MIC of <12.5 mg/L responded much better to treatment than those isolates with an MIC of 12.5 mg/L or greater. In 1986, Radetsky et al. 24 showed agreement with animal and clinical outcome with a broth microdilution method similar to the NCCLS microtitre method. They tested an isolate of C. albicans that was considered susceptible to flucytosine by both laboratory (MIC 2 mg/L) and clinical criteria, and an isolate of C. tropicalis that was considered resistant to flucytosine by the same criteria (MIC > 16 mg/L). Mice were infected and treated with 150 mg/kg per day flucytosine. All of the mice infected with the C. albicans isolate were still alive after 30 days, whereas all the mice infected with the C. tropicalis isolate had died within 3 days. Similar and more comprehensive results were obtained by Anaissie et al. 7 with multiple isolates of C. albicans, C. krusei and C. lusitaniae.
For C. albicans and, to a slightly lesser extent, C. tropicalis, many different testing formats appeared to give comparable results. Variation was limited in C. glabrata and C. parapsilosis, but few isolates had elevated MICs. Considerable variation in MICs was seen with C. krusei and C. lusitaniae.
In summary, substantial in vitro/in vivo correlation work needs to be undertaken to establish optimum susceptibility testing procedures with flucytosine for non-albicans Candida, particularly C. krusei. 
